Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 12, 2008, Pages 4241-4250

  Hurwitz, Selwyn J ^a,b   Asif, Ghazia ^a,b   Kivel, Nancy M ^c   Schinazi, Raymond F ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c RFS Pharma LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ENZYME; UNCLASSIFIED DRUG; ZIDOVUDINE; ZIDOVUDINE 5' MONOPHOSPHATE; ZIDOVUDINE 5' TRIPHOSPHATE; ZIDOVUDINE DERIVATIVE;

ADULT; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; KINETICS; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SIMULATION;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; KINETICS; MODELS, BIOLOGICAL; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 57049172088     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00054-08     Document Type: Article

References (90)

1. Acosta, E. P., L. M. Page, and C. V. Fletcher. 1996. Clinical pharmacokinetics of zidovudine. An update. Clin. Pharmacokinet. 30:251-262.
2. Anderson, P. L., T. N. Kakuda, S. Kawle, and C. V. Fletcher. 2003. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17:2159-2168.
3. Arner, E. S., T. Spasokoukotskaja, and S. Eriksson. 1992. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem. Biophys. Res. Commun. 188:712-718.
4. Arner, E. S., A. Valentin, and S. Eriksson. 1992. Thymidine and 3′-azido-3′-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages. A study of both anabolic and catabolic pathways. J. Biol. Chem. 267:10968-10975.
5. Balimane, P. V., and P. J. Sinko. 1999. Involvement of multiple transporters in the oral absorption of nucleoside analogues. Adv. Drug Deliv. Rev. 39:183-209.
6. Barry, M., M. Wild, G. Veal, D. Back, A. Breckenridge, R. Fox, N. Beeching, F. Nye, P. Carey, and D. Timmins. 1994. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 8(8):F1-F5.
7. Barry, M. G., S. H. Khoo, G. J. Veal, P. G. Hoggard, S. E. Gibbons, E. G. Wilkins, O. Williams, A. M. Breckenridge, and D. J. Back. 1996. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 10:1361-1367.
8. Bazmi, H. Z., J. L. Hammond, S. C. H. Cavalcanti, C. K. Chu, R. F. Schinazi, and J. W. Mellors. 2000. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 44:1783-1788.
9. Blum, M. R., S. H. Liao, S. S. Good, and P. de Miranda. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85:189-194.
10. Burger, D. M., P. L. Meenhorst, C. H. H. ten Napel, J. W. Mulder, C. Neef, C. H. Koks, A. Bult, and J. H. Beijnen. 1994. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions. AIDS 8:1683-1689.
11. Carpenter, C. C., D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 2000. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. JAMA 283:381-390.
12. Chen, H., R. F. Schinazi, P. Rajagopalan, Z. Gao, C. K. Chu, H. M. McClure, and F. D. Boudinot. 1999. Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. AIDS Res. Hum. Retrovir. 15:1625-1630.
13. Chien, J. Y., S. Friedrich, M. A. Heathman, D. P. de Alwis, and V. Sinha. 2005. Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J. 7:E544-E559.
14. Cohen, C. J., M. Kubota, P. S. Brachman, W. B. Harley, S. Schneider, V. C. Williams, D. H. Sutherland-Phillips, M. L. Lim, R. B. Balu, and M. S. Shaefer. 2008. Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study. Pharmacotherapy 28:314-322.
15. Collier, A. C., S. Bozzette, R. W. Coombs, D. M. Causey, D. A. Schoenfeld, S. A. Spector, C. B. Pettinelli, G. Davies, D. D. Richman, J. M. Leedom, et al. 1990. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N. Engl. J. Med. 323:1015-1021.
16. Cressey, T. R., P. Leenasirimakul, G. Jourdain, Y. Tawon, P. O. Sukrakanchana, and M. Lallemant. 2006. Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 42:387-389.
17. Darbyshire, J., M. Foulkes, R. Peto, W. Duncan, A. Babiker, R. Collins, M. Hughes, T. Peto, and A. Walker. 2000. Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults. Cochrane Database Syst. Rev. CD002039. doi:10.1002/14651858.CD002039.
18. de Clercq, E. 1996. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev. 16:125-157.
19. Deeks, S. G., M. Smith, M. Holodniy, and J. O. Kahn. 1997. HIV-1 protease inhibitors. A review for clinicians. JAMA 277:145-153.
20. Dudley, M. N. 1995. Clinical pharmacokinetics of nucleoside antiretroviral agents. J. Infect. Dis. 171(Suppl. 2):S99-S112.
21. el-Tahtawy, A. A., T. N. Tozer, F. Harrison, L. Lesko, and R. Williams. 1998. Evaluation of bioequivalence of highly variable drugs using clinical trial simulations. II: Comparison of single and multiple-dose trials using AUC and Cmax. Pharm. Res. 15:98-104.
22. Eriksson, B. F., C. K. Chu, and R. F. Schinazi. 1989. Phosphorylation of 3′-azido-2′,3′-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5′-triphosphate. Antimicrob. Agents Chemother. 33:1729-1734.
23. Eriksson, S., B. Kierdaszuk, B. Munch-Petersen, B. Oberg, and N. G. Johansson. 1991. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem. Biophys. Res. Commun. 176:586-592.
24. Faletto, M. B., W. H. Miller, E. P. Garvey, M. H. St. Clair, S. M. Daluge, and S. S. Good. 1997. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41:1099-1107.
25. Feng, J. Y., W. B. Parker, M. L. Krajewski, D. Deville-Bonne, M. Veron, P. Krishnan, Y. C. Cheng, and K. Borroto-Esoda. 2004. Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5′-phosphates by mammalian phosphotransferases. Biochem. Pharmacol. 68:1879-1888.
26. Fischl, M. A., D. D. Richman, D. M. Causey, M. H. Grieco, Y. Bryson, D. Mildvan, O. L. Laskin, J. E. Groopman, P. A. Volberding, R. T. Schooley, et al. 1989. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 262:2405-2410.
27. Fletcher, C. V., E. P. Acosta, K. Henry, L. M. Page, C. R. Gross, S. P. Kawle, R. P. Remmel, A. Erice, and H. H. Balfour, Jr. 1998. Concentration-controlled zidovudine therapy. Clin. Pharmacol. Ther. 64:331-338.
28. Flynn, P. M., J. Rodman, J. C. Lindsey, B. Robbins, E. Capparelli, K. M. Knapp, J. F. Rodriguez, J. McNamara, L. Serchuck, B. Heckman, and J. Martinez. 2007. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob. Agents Chemother. 51:3516-3522.
29. Foli, A., K. M. Sogocio, B. Anderson, M. Kavlick, M. W. Saville, M. A. Wainberg, Z. Gu, J. M. Cherrington, H. Mitsuya, and R. Yarchoan. 1996. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Antivir. Res. 32:91-98.
30. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, et al. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-8337.
31. Furman, P. A., J. Jeffrey, L. L. Kiefer, J. Y. Feng, K. S. Anderson, K. Borroto-Esoda, E. Hill, W. C. Copeland, C. K. Chu, J.-P. Sommadossi, I. Liberman, R. F. Schinazi, and G. R. Painter. 2001. Mechanism of action of 1-β-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-β-D-dioxolane guanosine. Antimicrob. Agents Chemother. 45:158-165.
32. Gao, W. Y., R. Agbaria, J. S. Driscoll, and H. Mitsuya. 1994. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
33. Gilliam, B. L., M. M. Sajadi, A. Amoroso, C. E. Davis, F. R. Cleghorn, and R. R. Redfield. 2007. Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population. AIDS Patient Care STDS 21:240-246.
34. Gitterman, S. R., G. L. Drusano, M. J. Egorin, H. C. Standiford, et al. 1990. Population pharmacokinetics of zidovudine. Clin. Pharmacol. Ther. 48:161-167.
35. Gripshover, B. M., H. Ribaudo, J. Santana, J. G. Gerber, T. B. Campbell, E. Hogg, B. Jarocki, S. M. Hammer, and D. R. Kuritzkes. 2006. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir. Ther. 11:619-623.
36. Gu, Z., M. A. Wainberg, N. Nguyen-Ba, L. L'Heureux, J. M. de Muys, T. L. Bowlin, and R. F. Rando. 1999. Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob. Agents Chemother. 43:2376-2382.
37. Gu, Z., M. A. Wainberg, P. Nguyen-Ba, L. L'Heureux, J. M. de Muys, and R. F. Rando. 1999. Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane. Nucleosides Nucleotides 18:891-892.
38. Hammond, J. L., D. L. Koontz, H. Z. Bazmi, J. R. Beadle, S. E. Hostetler, G. D. Kini, K. A. Aldern, D. D. Richman, K. Y. Hostetler, and J. W. Mellors. 2001. Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance. Antimicrob. Agents Chemother. 45:1621-1628.
39. Hammond, J. L., U. M. Parikh, D. L. Koontz, S. Schlueter-Wirtz, C. K. Chu, H. Z. Bazmi, R. F. Schinazi, and J. W. Mellors. 2005. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of β-2′,3′-didehydro-2′,3′-dideoxy-5- fluorocytidine. Antimicrob. Agents Chemother. 49:3930-3932.
40. Hellerstein, M., M. B. Hanley, D. Cesar, S. Siler, C. Papageorgopoulos, E. Wieder, D. Schmidt, R. Hoh, R. Neese, D. Macallan, S. Deeks, and J. M. McCune. 1999. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med. 5:83-89.
41. Hernandez-Santiago, B. I., H. Chen, G. Asif, T. Beltran, S. Mao, S. J. Hurwitz, J. Grier, H. M. McClure, C. K. Chu, D. C. Liotta, and R. F. Schinazi. 2005. Pharmacology and pharmacokinetics of the antiviral agent β-D-2′,3′-dideoxy-3′-oxa-5-fluorocytidine in cells and rhesus monkeys. Antimicrob. Agents Chemother. 49:2589-2597.
42. Hernandez-Santiago, B. I., A. Obikhod, E. Fromentin, S. J. Hurwitz, and R. F. Schinazi. 2007. Cellular pharmacology of 9-(beta-D-1,3-dioxolan-4- yl) guanine and its lack of drug interactions with zidovudine in primary human lymphocytes. Antivir. Chem. Chemother. 18:343-346.
43. Hirschhorn, R., G. Brittinger, K. Hirschhorn, and G. Weissmann. 1968. Studies on lysosomes. XII. Redistribution of acid hydrolases in human lymphocytes stimulated by phytohemagglutinin. J. Cell Biol. 37:412-423.
44. Hoggard, P. G., J. Lloyd, S. H. Khoo, M. G. Barry, L. Dann, S. E. Gibbons, E. G. Wilkins, C. Loveday, and D. J. Back. 2001. Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents. Antimicrob. Agents Chemother. 45:976-980.
45. Hsu, C.-H., R. Hu, G. E. Dutschman, G. Yang, P. Krishnan, H. Tanaka, M. Baba, and Y.-C. Cheng. 2007. Comparison of the phosphorylation of 4′-ethynyl 2′,3′-dihydro-3′-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs. Antimicrob. Agents Chemother. 51:1687-1693.
46. Hurwitz, S. J., G. Asif, and R. F. Schinazi. 2007. Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine. Antivir. Chem. Chemother. 18:329-341.
47. Hurwitz, S. J., and R. F. Schinazi. 2002. Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors. Antivir. Res. 56:115-127.
48. Jacobsson, B., S. Britton, Q. He, A. Karlsson, and S. Eriksson. 1995. Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. AIDS Res. Hum. Retrovir. 11:805-811.
49. Jacobsson, B., S. Britton, Y. Tornevik, and S. Eriksson. 1998. Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIV-infected individuals. Biochem. Pharmacol. 56:389-395.
50. Lanier, E. R., N. Givens, C. Stone, P. Griffin, D. Gibb, S. Walker, M. Tisdale, D. Irlbeck, M. Underwood, M. St. Clair, and M. Ait-Khaled. 2004. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med. 5:394-399.
51. Lavie, A., I. Schlichting, I. R. Vetter, M. Konrad, J. Reinstein, and R. S. Goody. 1997. The bottleneck in AZT activation. Nat. Med. 3:922-924.
52. Margolis, D. M., A. L. Mukherjee, C. V. Fletcher, E. Hogg, D. Ogata-Arakaki, T. Petersen, D. Rusin, A. Martinez, and J. W. Mellors. 2007. The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. AIDS 21:2025-2032.
53. Martin-Carbonero, L., P. Gil, T. Garcia-Benayas, P. Barreiro, F. Blanco, C. de Mendoza, I. Maida, J. Gonzalez-Lahoz, and V. Soriano. 2006. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients. AIDS Res. Hum. Retrovir. 22:1231-1235.
54. Merrill, D. P., M. Moonis, T. C. Chou, and M. S. Hirsch. 1996. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J. Infect. Dis. 173:355-364.
55. Mewshaw, J. P., F. T. Myrick, D. A. Wakefield, B. J. Hooper, J. L. Harris, B. McCreedy, and K. Borroto-Esoda. 2002. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. J. Acquir. Immune Defic. Syndr. 29:11-20.
56. Michelson, S., A. Sehgal, and C. Friedrich. 2006. In silico prediction of clinical efficacy. Curr. Opin. Biotechnol. 17:666-670.
57. Miller, R., W. Ewy, B. W. Corrigan, D. Ouellet, D. Hermann, K. G. Kowalski, P. Lockwood, J. R. Koup, S. Donevan, A. El-Kattan, C. S. Li, J. L. Werth, D. E. Feltner, and R. L. Lalonde. 2005. How modeling and simulation have enhanced decision making in new drug development. J. Pharmacokinet. Pharmacodyn. 32:185-197.
58. Ministry of Public Health, Thailand. 2005. National guidelines for the clinical management of HIV infection in children and adults. Ministry of Public Health, AIDS Division, Department of Communicable Disease Control, Nonthaburi, Thailand.
59. Mohri, H., A. S. Perelson, K. Tung, R. M. Ribeiro, B. Ramratnam, M. Markowitz, R. Kost, A. Hurley, L. Weinberger, D. Cesar, M. K. Hellerstein, and D. D. Ho. 2001. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J. Exp. Med. 194:1277-1287.
60. Munch-Petersen, B., L. Cloos, G. Tyrsted, and S. Eriksson. 1991. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J. Biol. Chem. 266:9032-9038.
61. Murphy, R., C. Zala, C. Ochoa, P. Tharnish, J. Mathew, E. Fromentin, G. Asif, S. J. Hurwitz, N. M. Kivel, and R. F. Schinazi. 2008. Pharmacokinetics and potent anti-HIV-1 activity of amdoxovir plus zidovudine in a randomized double-blind placebo-controlled study, abstr. 794. Abstr. 14th Conf. Retrovir. Opportunistic Infect. Boston, MA.
62. Nordic Medical Research Council HIV Therapy Group. 1992. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. BMJ 304:13-17.
63. Ogungbenro, K., and L. Aarons. 2007. Design of population pharmacokinetic experiments using prior information. Xenobiotica 37:1311-1330.
64. Ogungbenro, K., I. Gueorguieva, O. Majid, G. Graham, and L. Aarons. 2007. Optimal design for multiresponse pharmacokinetic- pharmacodynamic models - dealing with unbalanced designs. J. Pharmacokinet. Pharmacodyn. 34:313-331.
65. Panhard, X., M. Legrand, A. M. Taburet, B. Diquet, C. Goujard, and F. Mentre. 2007. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. Eur. J. Clin. Pharmacol. 63:1019-1029.
66. Parikh, U. M., L. Bacheler, D. Koontz, and J. W. Mellors. 2006. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J. Virol. 80:4971-4977.
67. Parikh, U. M., D. L. Koontz, C. K. Chu, R. F. Schinazi, and J. W. Mellors. 2005. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob. Agents Chemother. 49:1139-1144.
68. Pereira, C. F., and J. T. Paridaen. 2004. Anti-HIV drug development - an overview. Curr. Pharm. Des. 10:4005-4037.
69. Perez-Elias, M. J., S. Moreno, C. Gutierrez, D. Lopez, V. Abraira, A. Moreno, F. Dronda, J. L. Casado, A. Antela, and M. A. Rodriguez. 2005. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir. AIDS 19:695-698.
70. Plagemann, P. G., R. M. Wohlhueter, and C. Woffendin. 1988. Nucleoside and nucleobase transport in animal cells. Biochim. Biophys. Acta 947:405-443.
71. Rapp, K. L., M. Ruckstuhl, and R. F. Schinazi. 2007. The combination of zidovudine and amdoxovir prevents the selection of thymidine analogue mutations in primary human lymphocytes. Antivir. Ther. 12:S130.
72. Reardon, J. E., and W. H. Miller. 1990. Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5′-triphosphate and 3′-azido-3′-deoxythymidine 5′-triphosphate. J. Biol. Chem. 265:20302-20307.
73. Richman, D. D., M. A. Fischl, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, M. S. Hirsch, et al. 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317:192-197.
74. Rodriguez, J. F., J. L. Rodriguez, J. Santana, H. Garcia, and O. Rosario. 2000. Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals. Antimicrob. Agents Chemother. 44:3097-3100.
75. Rosario, M. C., B. Poland, J. Sullivan, M. Westby, and E. van der Ryst. 2006. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. J. Acquir. Immune Defic. Syndr. 42:183-191.
76. Ruane, P. J., and A. D. Luber. 2004. K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens. MedGenMed 6:31.
77. Ruane, P. J., G. J. Richmond, E. DeJesus, C. E. Hill-Zabala, S. C. Danehower, Q. Liao, J. Johnson, and M. S. Shaefer. 2004. Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapynaive patients infected with human immunodeficiency virus. Pharmacotherapy 24:307-312.
78. Sahai, J., K. Gallicano, E. Ormsby, G. Garber, and D. W. Cameron. 1994. Relationship between body weight, body surface area and serum zidovudine pharmacokinetic parameters in adult, male HIV-infected patients. AIDS 8:793-796.
79. Schinazi, R. F., B. I. Hernandez-Santiago, and S. J. Hurwitz. 2006. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antivir. Res. 71:322-334.
80. Siliciano, J. D., and R. F. Siliciano. 2004. A long-term latent reservoir for HIV-1: discovery and clinical implications. J. Antimicrob. Chemother. 54:6-9.
81. Siliciano, R. F. 2005. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. Top. HIV Med. 13:96-100.
82. Spiga, M. G., D. A. Weidner, C. Trentesaux, R. D. LeBoeuf, and J. P. Sommadossi. 1999. Inhibition of beta-globin gene expression by 3′-azido-3′-deoxythymidine in human erythroid progenitor cells. Antivir. Res. 44:167-177.
83. Stretcher, B. N., A. J. Pesce, P. T. Frame, and D. S. Stein. 1994. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:1541-1547.
84. Teague, T. K., L. Munn, K. Zygourakis, and B. W. McIntyre. 1993. Analysis of lymphocyte activation and proliferation by video microscopy and digital imaging. Cytometry 14:772-782.
85. Thompson, M. A., H. A. Kessler, J. J. Eron, Jr., J. M. Jacobson, N. Adda, G. Shen, J. Zong, J. Harris, C. Moxham, and F. S. Rousseau. 2005. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS 19:1607-1615.
86. Tornevik, Y., B. Jacobsson, S. Britton, and S. Eriksson. 1991. Intracellular metabolism of 3′-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res. Hum. Retrovir. 7:751-759.
87. Tornevik, Y., B. Ullman, J. Balzarini, B. Wahren, and S. Eriksson. 1995. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem. Pharmacol. 49:829-837.
88. Wainberg, M. A., M. D. Miller, Y. Quan, H. Salomon, A. S. Mulato, P. D. Lamy, N. A. Margot, K. E. Anton, and J. M. Cherrington. 1999. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir. Ther. 4:87-94.
89. White, K. L., N. A. Margot, T. Wrin, C. J. Petropoulos, M. D. Miller, and L. K. Naeger. 2002. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46:3437-3446.
90. Zhou, X.-J., L. B. Sheiner, R. T. D'Aquila, M. D. Hughes, M. S. Hirsch, M. A. Fischl, V. A. Johnson, M. Myers, J.-P. Sommadossi, and the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. 1999. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 43:121-128.